Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 490Rectal Neoplasms 267Colonic Neoplasms 218Pancreatic Neoplasms 184Stomach Neoplasms 181Esophageal Neoplasms 134Breast Neoplasms 118Neoplasm Metastasis 116Squamous Cell Carcinoma of Head and Neck 94Head and Neck Neoplasms 92Neoplasms 88Adenocarcinoma Of Esophagus 67Esophageal Squamous Cell Carcinoma 61Carcinoma, Hepatocellular 54Adenocarcinoma 40Nasopharyngeal Carcinoma 33Cholangiocarcinoma 31Biliary Tract Neoplasms 26Anus Neoplasms 26Gastrointestinal Neoplasms 25Carcinoma, Squamous Cell 25Carcinoma, Non-Small-Cell Lung 25Keratosis, Actinic 22Gallbladder Neoplasms 21Urinary Bladder Neoplasms 20Parkinson Disease 4, Autosomal Dominant Lewy Body 20Liver Neoplasms 20Bile Duct Neoplasms 19Ovarian Neoplasms 16Carcinoma 16

Interventions

Leucovorin 2Irinotecan 2Fluorouracil 2Cetuximab 2spartalizumab 1pembrolizumab 1camrelizumab 1Radiosurgery 1Oxaliplatin 1Oncolytic Virotherapy 1KD025 1IFL protocol 1HLX07 1Folfox protocol 1Drug Therapy 1CCT239065 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × CRC × Fluorouracil × Clear all
NCT07381309 2026-04-28

VVSHIP

Sixth Affiliated Hospital, Sun Yat-sen University

Phase 2 Not yet recruiting
114 enrolled
Gastrointestinal

CRC

NCT07204574 2025-10-02

The Phase 1b/IIa, Open-label, Dose Escalation and Dose Expansion to Evaluate Safety, Tolerability, and Preliminary Efficacy of the Combination of HCB101, Cetuximab/Bevacizumab, and FOLFOX/FOLFIRI in Advanced or Metastatic Colorectal Cancer

Chang Gung Memorial Hospital

Phase 1/2 Recruiting
40 enrolled

CRC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡